In patients with untreated, EGFR-mutated advanced NSCLC, overall survival is improved with the third-generation EGFR TKI osimertinib compared with the first-generation TKIs gefitinib and erlotinib [11]. Here, EGFR is linked to non-small cell lung carcinoma.